Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antigenics Inc.
Antigenics’ QS-21 Adjuvant Enters Pivotal Phase 3 Clinical Trial of GlaxoSmithKline’s Malaria Vaccine
July 1st, 2009
Antigenics Inc. (NASDAQ: AGEN) announced that GlaxoSmithKline (GSK) has launched a Phase 3 study with the world's most clinically-advanced malaria vaccine, RTS,S, which contains Antigenics' QS-21 Stimulon® adjuvant. "There are now approximately 15 vaccines containing QS-21 in clinical trials of which four have now progressed into Phase 3 studies across multiple indications including non-small cell lung cancer, melanoma and malaria," said Garo H. Armen, PhD, chairman and CEO of Antigenics. "The announcement demonstrates that QS-21 is a critical adjuvant in the development of therapeutic and prophylactic vaccines and is expected to be a significant contributor to...
Source: Vaccine Weekly (2009-07-01)
|
